

[ORIGINAL ARTICLE]

Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine

Wataru Takahashi¹, Toshiko Mizuno¹, Kaori Hara², Yoshiaki Ara³, Rikiya Hurutani⁴,
Toshihiko Agatsuma² and Minoru Fujimori⁵

Abstract:

Objectives The influential factors for anti-severe acute respiratory syndrome coronavirus 2 spike protein antibody (S-ab) levels were assessed after the administration of BNT162b2 mRNA coronavirus disease-2019 (COVID-19) vaccine at short and medium terms.

Methods A total of 470 healthcare workers (118 males, mean age 41.0±11.9 years) underwent serum S-ab level measurement at 3 and 8 months after two inoculations of BNT162b2 vaccine given 3 weeks apart, who had no history of COVID-19 were enrolled in this study. The changes and differences after vaccination due to gender and adverse reactions of S-ab were analyzed.

Results Systemic adverse reactions incidence (48%) was significantly higher after the second dose than after the first dose (8%). S-ab levels decreased as the age increased (from the 20s to 60s) in both measurements. S-ab level 8 months after the second inoculation (median 476.3 [interquartile range {IQR} 322.4-750.6] U/mL) was significantly lower than that after 3 months (977.5 [637.2-1409.0] U/mL; $P < 0.001$). The median decrease rate of S-ab levels in 5 months was 50.3 (IQR 40.3-62.6) % and those differences were not observed among all generations. Gender-associated differences in S-ab levels were not observed; however, a significant relationship between higher S-ab levels and the systemic adverse reactions was observed at both measurements.

Conclusions The systemic adverse reaction is an independent factor for higher S-ab levels at short and medium terms after BNT162b2 vaccination as demonstrated in our data.

Key words: COVID-19, BNT162b2 mRNA COVID-19 vaccine, Anti-SARS-CoV-2 spike protein antibody

(Intern Med Advance Publication)

(DOI: 10.2169/internalmedicine.9699-22)

Introduction

The coronavirus disease-2019 (COVID-19) pandemic has been severely damaging the global health and economic structures caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continuing for about 2 years. Under these circumstances, great expectations are placed on mass vaccination that might control the spread of

the virus. In Japan, the two-dose administration of BNT162b2 mRNA COVID-19 vaccine was given to healthcare professionals in February 2021, followed by two doses of Moderna mRNA-1273 COVID-19 vaccine that was started in May 2021. About 78% of the total population had completed two inoculations by the end of January 2022 (1). SARS-CoV-2 consists of four structural proteins: spike, envelope, membrane, and nucleocapsid encoded by a single, positive-standard RNA genome (2). Viral invasion is

¹Department of Clinical Research, National Hospital Organization, Shinshu Ueda Medical Center, Japan, ²Department of Infection Control, National Hospital Organization, Shinshu Ueda Medical Center, Japan, ³Department of Pharmacy, National Hospital Organization, Shinshu Ueda Medical Center, Japan, ⁴Department of Neurology, National Hospital Organization, Shinshu Ueda Medical Center, Japan and ⁵Department of Breast Surgery, National Hospital Organization, Shinshu Ueda Medical Center, Japan

Received: March 3, 2022; Accepted: July 6, 2022; Advance Publication by J-STAGE: August 20, 2022

Correspondence to Wataru Takahashi, takahashi.wataru.fu@mail.hosp.go.jp

achieved through membrane fusion of the virus and host cells as the spike protein mediates receptor-binding on the host cells (3). BNT162b2 vaccine was mRNA-based encoding the receptor-binding domain of the spike protein with 95% efficacy in preventing symptomatic COVID-19 among individuals without previous infection (4). The association between reactogenicity and anti-SARS-CoV-2 spike protein antibody (S-ab) levels after the vaccination has been discussed in several studies as much research progresses on the factors that can influence S-ab levels after inoculation of BNT162b2 vaccine (5). It has actually been reported that the second inoculation obtains higher S-ab levels than the first inoculation of BNT162b2 vaccine, but the frequency of adverse reactions also increases (4). This implies that reactogenicity might be related to S-ab levels after vaccination. However, no uniform view has been obtained while epidemiological data regarding the relevance between reactogenicity and immunogenicity after administration of BNT162b2 vaccine remains limited. We report a single-center study here that measured S-ab levels in the short and medium terms after two inoculations of the BNT162b2 vaccine in all kinds of healthcare workers at our hospital. We then analyzed the change of S-ab levels, and the factors that influence them.

Materials and Methods

The study included all hospital workers who were two-dose vaccinated with BNT162b2 vaccine for 3 weeks, from February to March 2021, measured S-ab levels two times at 3 and 8 months after vaccination on request, were judged to have no SARS-CoV-2 infection before the second examination, and agreed to the analysis. History of SARS-CoV-2 infection was judged based on their medical history including daily evaluation of body temperature and related symptoms and results of SARS-CoV-2 antigen test of nasopharyngeal swabs using Lumipulse® (FUJIREBIO Co., Tokyo, Japan), chemiluminescent enzyme immunoassay system, when fever is $\geq 37.5^{\circ}\text{C}$. Current infection was diagnosed based on the polymerase chain reaction test of nasopharyngeal swabs using Ampdirect 2019-nCoV kit (SHIMADZU Co., Kyoto, Japan) if participants declared a close contact with patients with SARS-CoV-2 or had suggestive symptoms, such as fever, sore throat, headache, cough, nasal congestion, ageusia, and anosmia. Blood samples were collected twice during regular medical examinations at 3 months and 8 months after inoculation, and serum antibody levels were measured immediately after sampling with SARS-CoV-2 IgG assay using Elecsys® Anti-SARS-CoV-2 S RUO (Roche Diagnostics Co., Rotkreuz, Switzerland). This system targets the receptor-binding domain of the SARS-CoV-2 spike protein and allows the quantitative evaluation of antibodies, predominantly IgG. Vaccine adverse reactions were recorded separately for local and systemic events based on the structured self-reported questionnaire. Notable local adverse reactions were defined as pain that requires treatment, redness,

swelling, or induration with a diameter of ≥ 2 cm, itching and heat at the administration site, and blisters. Notable systemic adverse reactions were defined as fever of $\geq 38^{\circ}\text{C}$, rashes, moderate to severe headache, fatigue, runny nose requiring treatment, anaphylaxis, severe or widespread pruritus, vomiting of more than twice a day, and diarrhea of ≥ 6 times a day. The study was approved by the local institutional ethics review board, and all participants signed an informed consent.

Statistical analysis

Categorical variables in participant characteristics are presented as absolute numbers (n), relative frequencies (%), and mean and standard deviation. Non-parametric continuous data are expressed as the median with interquartile range (IQR). The frequency of vaccine adverse reactions between age groups was compared using the chi-square test, and between-group comparisons of S-ab levels were performed using Wilcoxon Mann-Whitney U test. Significant predictors of S-ab levels after vaccination were identified using the multivariate log-normal analysis. A P -value significance threshold of $P < 0.05$ was used. All statistical analyses were performed using the Statistical Package for the Social Sciences (IBM, SPSS version 25; Armonk, NY, USA).

Results

Of the 505 hospital employees who received two inoculations of the BNT162b2 mRNA COVID-19 vaccine, 17 and 15 moved or left before the first and second serum S-ab measurements, respectively. Two participants who did not receive the second dose due to allergic reactions during the first one and a participant who was infected with SARS-CoV-2 before the second S-ab measurement were excluded from the analysis. Finally, 470 employees aged 22-69 (mean, 41.0 ± 11.9) years comprising of 118 males were included for analysis. All participants consisted of 51 doctors, 207 nurses, 10 pharmacists, 146 para-medical staffs, and 56 clerks and nursing school staffs. Baseline characteristics are presented in Table 1. The numbers of participants were almost the same from the 20s to 50s, except for the 60s which had fewer participants, and all generations had a female predominance distribution with a female ratio of 75%. Hypertension was the most common comorbidity in 20 participants (4%), followed by dyslipidemia in 8 participants (1%). Furthermore, there were participants with rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, and primary aldosteronism; 3, 1, 1, and 1, respectively. The occurrence of vaccine adverse reactions is shown in Table 2. Both notable local and systemic adverse reactions significantly occurred more frequently after the second dose than after the first one. Although no participant had a fever of $\geq 38^{\circ}\text{C}$ after the first vaccination, 22% had a fever after the second vaccination (20s, 33%; 30s, 24%; 40s, 19%; 50s, 15%; and 60s, 7%). Moreover, the younger generation had more sys-

temic adverse reactions including fever. Serum S-ab level 8 months after the second inoculation (median 476.3 [IQR 322.4-750.6] U/mL) was significantly lower than that after 3 months (977.5 [637.2-1,409.0] U/mL; $P < 0.001$) (Fig. 1A). S-ab levels decreased as the age increased from the 20s to 60s both at 3 months in the analysis by age (20s, 1401 [IQR 826.5-1,988]; 30s, 1061 [IQR 689.3-1,427.0]; 40s, 867.0 [IQR 614.5-1,280.5]; 50s, 803.8 [IQR 482.8-1,227.0]; and 60s 891.1 [IQR 528.4-1,099.3] U/mL; $P < 0.001$) and 8 months (20s, 621.4 [IQR 379.0-965.4]; 30s, 476.3 [339.1-747.6]; 40s, 456.0 [328.2-634.6]; 50s, 426.4 [226.7-624.6]; and 60s, 452.5 [265.3-616.6] U/mL; $P < 0.001$) after vaccination (Fig. 1B). The median decrease rate in S-ab levels

from 3 to 8 months after vaccination (the ratio of S-ab level after 8 months to that after 3 months) was 50.3 (IQR 40.3-62.6)% on all participants, and no significant difference was observed among generations (20s, 47.6 [IQR 38.8-57.5]; 30s, 49.7 [IQR 38.5-61.4]; 40s, 50.1 [IQR 40.7-66.0]; 50s, 51.9 [IQR 43.5-63.1]; and 60s, 46.7 [IQR 34.6-67.5]%). No significant difference in the antibody level was observed between men and women at two measurements (Fig. 2). The antibody levels 8 months after vaccination in 13 participants (median 812.0 [IQR 495.0-986.3] U/mL) were higher than after 3 months (median 529.2 [IQR 439.4-873.1] U/mL), although it was insignificant. The distribution of S-ab level peaked at the range of 600-799 U/mL and spread widely 3 months after vaccination; however, the majority of the population had a low antibody level of 200-399 U/mL 8 months after it. Regarding the analysis about the relationship between vaccine adverse reactions and S-ab level, the antibody levels of participants with systemic adverse reactions after the first dose were significantly higher than those without it at both measurements. Moreover, similar results were obtained regarding the systemic adverse reactions after the second dose (Fig. 3). The age of 20s was significantly associated with S-ab level 3 months after vaccination and the presence of systemic adverse reactions after the second dose was significantly associated with high S-ab level at two measurements in multivariate log-normal analysis (Table 3). However, no significant association was observed between the local adverse reactions and S-ab levels in any analysis.

Table 1. Baseline Characteristics of Participants Data are Presented as n (%), Except for Displaying Age As mean (SD, standard deviation).

Participants characteristics (n=470)		values
Age y.o., mean (SD)		41.0 (11.9)
Male, n (%)		118 (25)
Generation	20-29 y.o., n (%)	108 (23)
	male, n (%)	20 (19)
	30-39 y.o., n (%)	105 (22)
	male, n (%)	35 (33)
	40-49 y.o., n (%)	128 (27)
	male, n (%)	28 (22)
	50-59 y.o., n (%)	105 (22)
	male, n (%)	27 (26)
	60 y.o. -, n (%)	24 (5)
	male, n (%)	8 (33)
Hypertension, n (%) *		20 (4)
Dyslipidemia, n (%) *		8 (1)
Collagen disease, n (%) *		5 (1)
Bronchial asthma, n (%) *		3 (1)
Diabetes mellitus, n (%) *		2 (1)
Endocrine disease, n (%) *		2 (1)
Depression, n (%) *		3 (1)
Previous history of malignancy disease, n (%) †		3 (1)
Immunosuppressant therapy, n (%)		1 (1)

* Prescribed as requiring year-round medication. † Included a participant after a lung cancer surgery and two participants after breast cancer surgery.

Discussion

S-ab levels significantly decreased by approximately 50% from 3 to 8 months after vaccination in all generations in this survey with two serum S-ab level measurements in the short and medium term after two administrations of BNT 162b2 mRNA COVID-19 vaccine for the hospital staff. This change of S-ab level was consistent with the results in previous reports. A previous study in Japan also reported a 68.9% reduction of S-ab levels from 3 to 6 months after the two-dose BNT162b2 vaccine (6). Although no evidence has been reported regarding the association of decreased SARS-CoV-2 antibodies with increased infection risk, this finding

Table 2. The Occurrence of Vaccine Adverse Reactions after the First and Second Doses of Vaccination.

Age	n	1st dose		2nd dose	
		focal reaction	systemic reaction	focal reaction	systemic reaction
20-29 y.o., n (%)	108	52 (48)	11 (10)	63 (58)	66 (61) †
30-39 y.o., n (%)	106	42 (40)	14 (13)	51 (48)	53 (50) †
40-49 y.o., n (%)	130	55 (42)	7 (5)	65 (50)	61 (47) †
50-59 y.o., n (%)	103	33 (32)	6 (6)	56 (54) §	40 (39) †
60 y.o. -, n (%)	27	11 (41)	1 (4)	13 (48)	6 (22) ‡
total, n (%)	470	193 (41)	39 (8)	248 (53)	226 (48)

† $p < 0.001$; ‡ $p = 0.048$; § $p = 0.001$ vs 1st dose




Figure 1. S-ab levels 3 and 8 months after the second vaccination dose in all participants and participants in each generation. The top and bottom of a box represent IQR; a horizontal line, the median; and whiskers, the minimum and maximum values. Circles and asterisks represent outliers and extreme outliers, respectively. A: S-ab levels at two measurements in all participants. Undetectable S-ab levels of <0.4 (at two measurements of 1 participant) and $\geq 5,000$ U/mL (at the first measurements of 2 participants) were imputed with 0.4 U/mL and 5,000 U/mL, respectively. B: Generational S-ab levels at two measurements. 3M: 3 months, 8M: 8 months




Figure 2. S-ab levels by gender at 3 and 8 months after the second dose of vaccination. F: female, M: male

showing a rapid decline in antibody levels to near depletion in 8 months following inoculation is very meaningful supportive data when considering the validity of the third booster inoculation. The most impressive finding in our study is the significant relationship between systemic adverse reactions and serum S-ab level after vaccination. A significant association between reactogenicity and immune response after vaccination has been reported in some studies (7). Antigenic priming of the immune system during the first vaccination can increase reactogenicity following the

booster inoculation (8). This might be the mechanism that results in the significant association between systemic reactogenicity and intense immune response after the second vaccination as in this study. The overall low incidence frequency and the low severity of adverse reactions in the older cohort with immunosenescence may be consistent with this result. Remarkably, the number of participants in their 60s with moderate or greater systemic adverse reactions after the second vaccination was one-third of those in their 20s in this study. However, the epidemiological study results of af-




Figure 3. S-ab levels of participants from each group after 3 and 8 months, divided into those who had a systemic adverse reaction at the time of vaccination and those who did not. SR: systemic adverse reaction

Table 3. Multivariate Log-normal Analysis of Factors Contributing to S-ab Levels 3 and 8 Months After Vaccination.

Variables	3M			8M		
	Value	t value	p value	Value	t value	p value
Age (20s)	454.00	2.95	0.003	179.76	1.76	0.079
Gender, female	30.01	0.41	0.686	-17.02	-0.35	0.724
Systemic adverse reaction after the 1st dose	-129.24	-1.13	0.259	-54.30	-0.73	0.466
Systemic adverse reaction after the 2nd dose	-0.21	-3.11	0.002	-149.65	-3.37	0.001

ter COVID-19 vaccination are inconsistent based on the association between systemic adverse reactions and anti-SARS-CoV-2 antibody levels. A study showed a fever of $\geq 38^{\circ}\text{C}$ after two doses of the BNT162b2 vaccine was related with higher S-ab levels, but no association between systemic adverse reaction grades and S-ab levels (5). In another study, there was no difference in S-ab levels according to local and systemic adverse reaction grades after the BNT162b2 or AZD1222 two-dose vaccine (9). The small sample size on these studies could be a reason for the dissociation from our study results. Further analysis buildup from large scale studies are needed. Nevertheless, it is noted that immunoreactivity to the vaccine might be predicted based on the presence of the systemic adverse reactions. Another important finding in this study is the relationship between gender and S-ab levels. Our study showed that antibody levels tended to be higher in females than in males both at 3 and 8 months after vaccination; however, no significant difference was confirmed. A study investigating antibody levels showed that the serum levels of IgG antibody against SARS-CoV-2 was lower by 16% in males than females up to 5 weeks after vaccination in healthcare workers (10). In addition, a study reporting a high aggravation rate of SARS-CoV-2 infection

in males suggested a poor immune response to SARS-CoV-2 (11). The main reason why no gender difference was observed in S-ab levels in this study is probably due to the limited number of participants and the unique cohort characteristics with the female-dominated uneven gender distribution. The analysis in the general population is needed to clarify the gender difference of immune response to SARS-CoV-2 vaccine. The relationship between age and S-ab levels is a controversial issue in our study. Several studies have suggested an association between age and post-inoculation antibody levels during the early phase after vaccination (6, 12). The younger generation also tended to have higher S-ab levels both at 3 and 8 months after vaccination in our study, and the decreased rates of S-ab levels in 5 months were similar for all generations. However, the elderly ratio of over 60 years of age is low, and we have no data for those over 70 years of age. Therefore, we could not prove immunogenicity inferiority of the elderly to the vaccine in this study. Nonetheless, it is clear from the results of randomized trial that vaccine efficacy of 86% to 100% can be obtained in all generations for SARS-CoV-2 infection prevention (13). Interestingly, 13 of 400 participants had higher S-ab levels at 8 months than at 3 months after vacci-

nation. All had no evidence of infection or close contact with an infected individual during the observation period. This is significantly different from the general antibody level movement, which peaks just after the second dose and then gradually declines thereafter, as revealed in previous studies (14). Some lifestyle habits such as drinking, weight gain, smoking and immunosuppressants have also been reported to affect antibody levels (12). Further examination is needed to elucidate the pathology of unique S-ab level movement in these participants. It should be recognized that some individuals could continue to maintain the same antibody level after vaccination. This study has several limitations. First, as mentioned above, this study has a marked bias in the female-dominated cohort, and is for healthcare professionals. It does not reflect worldwide data. Furthermore, healthcare workers could have more opportunities for high exposure to COVID-19 rather than the general population. It is quite difficult to differentiate previous asymptomatic-infected persons based on their medical history and physical findings alone. Second, no data was available on participants' preferences such as drinking or smoking, so that their effects on antibody levels could not be included in the analysis. Third, we could not speculate the mechanism of the relationship between systemic adverse reactions and S-ab level after vaccination as we did not have immunological data such as cytokines. In conclusion, this report highlights that the presence of systemic adverse reactions after the second dose was significantly associated with S-ab levels after the administration of the BNT162b2 mRNA COVID-19 vaccine in all generations. We hope that more research will be undertaken to prove this because evidence is inconsistent in the previous studies.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We appreciate all participants who agreed to this study and all staff involved in the vaccination schedule at the National Hospital Organization Shinshu Ueda National Hospital as well as Mr. Toshitaka Maejima, Mr. Ryuichi Matsumoto, and Mr. Hiroya Mizusawa for cooperating and conducting the survey.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contributions

Minoru Fujimori was responsible for the organization and coordination of the trial. Wataru Takahashi was the chief investigator and responsible for the data analysis. Rikiya Hurutani and Toshihiko Agatsuma developed the trial design. Wataru Takahashi and Toshiko Mizuno performed data analysis. Kaori Hara and Yoshiaki Ara commented on the manuscript. All members of the study team contributed to the management or administration of the trial.

Ethical approval

This study was approved by the independent ethics committee of National Hospital Organization Shinshu Ueda National Hospital and was based on the principles of the Declaration of Helsinki. Informed consent was obtained from all participants after explaining the study protocol.

References

1. Prime minister of Japan and His cabinet. Information related to COVID-19 [Internet]. Available from: <https://japan.kantei.go.jp/ongoingtopics/vaccine.html>
2. Xia X. Domains and functions of spike protein in Sars-Cov-2 in the context of vaccine design. *Viruses* **13**: 109, 2021.
3. Huang Y, Chan Y, Xin-Feng X, Wei X, Shu-Wen L. Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacol Sin* **41**: 1141-1149, 2020.
4. Polack FP, Thomas ST, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* **385**: 1761-1773, 2021.
5. Yamamoto S, Fukunaga A, Tanaka A, et al. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. *Vaccine* **18**: 1924-1927, 2022.
6. Mochizuki T, Hori T, Yano K, Ikari K, Okazaki K. Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study. *Intern Med* 8902-8921, 2022, DOI: 10.2169/internalmedicine
7. Oyeibanji OA, Wilson B, Keresztesy D, et al. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? *Aging Clin Exp Res* **33**: 3151-3160, 2021.
8. Florian K, Srivastava K, Alshammary H, et al. Antibody responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**: 1372-1374, 2021.
9. Hwang YH, Song KH, Choi Y, et al. Can reactogenicity predict immunogenicity after COVID-19 vaccination? *Korean J Intern Med* **36**: 1486-1491, 2021.
10. Yaniv L, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir Med* **9**: 999-1009, 2021.
11. Giacomo G, Zangrillo A, Zanella A, et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* **323**: 1574-1581, 2020.
12. Kageyama T, Ikeda K, Tanaka S, et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. *Clin Microbiol Infect* **27**: 1861.e1-1861.e5, 2021.
13. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* **385**: 1761-177★, 2021.
14. Montoya JG, Amy EA, Valérie B, et al. Differences in IgG antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. *Microbiol Spectr* **9**: e0116221, 2021.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

© The Japanese Society of Internal Medicine
Intern Med Advance Publication